About Us

Hahn-Jun Lee, M.Sc., Ph.D.

Dr. Lee is a serial entrepreneur who founded Polaryx Therapeutics, Inc to develop patient-friendly oral drugs for lysosomal storage disorders, such as Neuronal Ceroid Lipofuscinosis, Niemann Pick disease, Tay Sachs disease, and Krabbe disease which are devastating pediatric genetic disorders. He founded Epygenix Therapeutics, Inc. to develop precision medicines for rare and intractable genetic epilepsies, such as Dravet syndrome and Curyx Bio, Inc. to develop fist-in-class drugs for Parkinson’s Disease, Huntington’s Disease, and Glycine Encephalopathy. He also founded Focus Therapeutics, L.L.C. which plays a catalytic role in US and Asian Pacific biotechnology companies.

He has extensive experiences in R&D, deal making, business development, and consulting for top-notch health care venture capital firms and global pharma and biotech companies including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He has also consulted Korean biotechs, venture capital firms, and research institutes.

Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.

He obtained his B.S. in Life Science from Sogang University, Seoul, Korea. He obtained his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology from the University of Tokyo, Japan.

Dr. Kalipada Pahan, Ph.D

Dr. Pahan is a Professor of Neurological Sciences, Biochemistry and Pharmacology and the Floyd A. Davis, M.D., Endowed Chair in Neurology at the Rush University Medical Center in Chicago. He is also a Veterans Affairs Scientist at the Jesse Brown VA Medical Center. Currently, he is engaged in translational biomedical research involving Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, and Batten Dsease. He is the Editor-in-Chief of the Journal of Multiple Sclerosis, Senior Editor of the Journal of Neuroimmune Pharmacology, Editor of three other journals, and a chartered member of the Clinical Neuroimmunology and Brain Tumors study section at the NIH.

He has over 160 publications and is cited by Wikipedia. He received the outstanding teaching award in 2000, the “Chancellor’s Council Silver U Award” in 2004 and the "Reinhardt Research Scholar Award” in 2005 from the University of Nebraska Medical Center. Recently he also received VA merit awards from the US Department of Veterans Affairs and the Zenith award from the Alzheimer’s Association.

Dr. Raymond Y. Wang, M.D.

Dr. Raymond Wang, M.D. is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s Hospital and a board certified clinical geneticist and biochemical genetics specialist. Dr. Wang is aware of the challenges faced by patients and families with rare diseases such as lysosomal storage disorders. He has committed the program to provide: treatment for the lysosomal disorders that have existing therapies; access to investigational treatment for patients with disorders that currently have no approved / effective therapy, and translational research vital to development of “next generation” treatments and cures for lysosomal storage disorder patients. He has participated in clinical trials for Type 2 Neuronal Ceroid Lipofuscinosis, Pompe Disease, Niemann-Pick C Disease, and Mucopolysaccharidoses. He also is the principal investigator for translational research involving gene therapy and gene editing for treatment of lysosomal storage disorders.

Dr. Wang graduated from Stanford University with Honors and Distinction in Biological Sciences. He earned his medical degree from the University of California, Los Angeles (UCLA), and completed his internship and residency in medical genetics and pediatrics at Cedars-Sinai Medical Center where he served as chief resident in his final year of training. Dr. Wang completed his fellowship in biochemical genetics at the UCLA Intercampus Medical Genetics Program. In 2006, Dr. Wang received the American College of Medical Genetics and Genzyme Fellowship in Biochemical Genetics Award and the Cedars-Sinai Medical Center’s Paul Rubenstein Prize for Excellence in Resident Research. Dr. Wang has been named an Orange County Clinical Biochemical Genetics Physician of Excellence in 2015, 2016, 2017, 2018, and 2019 and nominated for a 2018 Global Genes RARE Champion of Hope Award for his work with children with rare metabolic conditions.